1. National Institute for Health and Care Excellence . Vedolizumab for treating moderately to severely active ulcerative colitis (TA342), 2015. Available: https://www.nice.org.uk/guidance/ta342/ [Accessed 7 Nov 2022].
2. National Institute for Health and Care Excellence . Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy (TA352), 2015. Available: https://www.nice.org.uk/guidance/ta352/ [Accessed 7 Nov 2022].
3. Entyvio 300 mg powder for concentrate for solution for infusion. Summary of Product Characteristics, GB. Takeda Pharma A/S, March 2022.
4. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
5. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease